Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα).
Rej RK, Hu B, Chen Z, Acharyya RK, Wu D, Metwally H, McEachern D, Wang Y, Jiang W, Bai L, Nishimura LS, Gersch CL, Wang M, Wen B, Sun D, Carlson K, Katzenellenbogen JA, Xu G, Zhang W, Wu W, Priestley ES, Sui Z, Rae JM, Wang S. Rej RK, et al. Among authors: priestley es. J Med Chem. 2024 Nov 25. doi: 10.1021/acs.jmedchem.4c01401. Online ahead of print. J Med Chem. 2024. PMID: 39585895
Discovery of Potent, Highly Selective, and Efficacious SMARCA2 Degraders.
Li Z, Harikrishnan LS, Xu G, Samanta D, Clemente JC, Leng L, Tu W, Yang L, Huang L, Wang M, Wang S, Deng Q, Behshad E, Nagilla R, Orth P, Rice C, Strickland C, Mohammad HP, Priestley ES, Sui Z. Li Z, et al. Among authors: priestley es. J Med Chem. 2024 Nov 21. doi: 10.1021/acs.jmedchem.4c01878. Online ahead of print. J Med Chem. 2024. PMID: 39570797
Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer.
Acharyya RK, Rej RK, Hu B, Chen Z, Wu D, Lu J, Metwally H, McEachern D, Wang Y, Jiang W, Bai L, Tošović J, Gersch CL, Xu G, Zhang W, Wu W, Priestley ES, Sui Z, Sarkari F, Wen B, Sun D, Rae JM, Wang S. Acharyya RK, et al. Among authors: priestley es. J Med Chem. 2024 Nov 14;67(21):19010-19037. doi: 10.1021/acs.jmedchem.4c01521. Epub 2024 Nov 1. J Med Chem. 2024. PMID: 39485242
Discovery of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor for the Treatment of Heart Failure.
Richter JM, Gunaga P, Yadav N, Bora RO, Bhide R, Rajugowda N, Govindrajulu K, Godesi S, Akuthota N, Rao P, Sivaraman A, Panda M, Kaspady M, Gupta A, Mathur A, Levesque PC, Gulia J, Dokania M, Ramarao M, Kole P, Chacko S, Lentz KA, Sivaprasad Lvj S, Thatipamula RP, Sridhar S, Kamble S, Govindrajan A, Soleman SI, Gordon DA, Wexler RR, Priestley ES. Richter JM, et al. Among authors: priestley es. J Med Chem. 2024 Jun 13;67(11):9731-9744. doi: 10.1021/acs.jmedchem.4c00893. Epub 2024 May 29. J Med Chem. 2024. PMID: 38807539
Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis.
Zhang X, Jiang W, Richter JM, Bates JA, Reznik SK, Stachura S, Rampulla R, Doddalingappa D, Ulaganathan S, Hua J, Bostwick JS, Sum C, Posy S, Malmstrom S, Dickey J, Harden D, Lawrence RM, Guarino VR, Schumacher WA, Wong P, Yang J, Gordon DA, Wexler RR, Priestley ES. Zhang X, et al. Among authors: priestley es. J Med Chem. 2024 Mar 14;67(5):3571-3589. doi: 10.1021/acs.jmedchem.3c01986. Epub 2024 Feb 22. J Med Chem. 2024. PMID: 38385264
Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4.
Priestley ES, Banville J, Deon D, Dubé L, Gagnon M, Guy J, Lapointe P, Lavallée JF, Martel A, Plamondon S, Rémillard R, Ruediger E, Tremblay F, Posy SL, Guarino VR, Richter JM, Li J, Gupta A, Vetrichelvan M, Balapragalathan TJ, Mathur A, Hua J, Callejo M, Guay J, Sum CS, Cvijic ME, Watson C, Wong P, Yang J, Bouvier M, Gordon DA, Wexler RR, Marinier A. Priestley ES, et al. J Med Chem. 2022 Jul 14;65(13):8843-8854. doi: 10.1021/acs.jmedchem.2c00359. Epub 2022 Jun 21. J Med Chem. 2022. PMID: 35729784
Microscale purification in support of high-throughput medicinal chemistry.
Barhate CL, Donnell AF, Davies M, Li L, Zhang Y, Yang F, Black R, Zipp G, Zhang Y, Cavallaro CL, Priestley ES, Weller HN. Barhate CL, et al. Among authors: priestley es. Chem Commun (Camb). 2021 Oct 21;57(84):11037-11040. doi: 10.1039/d1cc03791a. Chem Commun (Camb). 2021. PMID: 34608906
Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy.
Miller MM, Banville J, Friends TJ, Gagnon M, Hangeland JJ, Lavallée JF, Martel A, O'Grady H, Rémillard R, Ruediger E, Tremblay F, Posy SL, Allegretto NJ, Guarino VR, Harden DG, Harper TW, Hartl K, Josephs J, Malmstrom S, Watson C, Yang Y, Zhang G, Wong P, Yang J, Bouvier M, Seiffert DA, Wexler RR, Lawrence RM, Priestley ES, Marinier A. Miller MM, et al. Among authors: priestley es. J Med Chem. 2019 Aug 22;62(16):7400-7416. doi: 10.1021/acs.jmedchem.9b00186. Epub 2019 Aug 5. J Med Chem. 2019. PMID: 31246024
Correction to "Atropisomer Control in Macrocyclic Factor VIIa Inhibitors".
Glunz PW, Mueller L, Cheney DL, Ladziata V, Zou Y, Wurtz NR, Wei A, Wong PC, Wexler RR, Priestley ES. Glunz PW, et al. Among authors: priestley es. J Med Chem. 2018 Apr 26;61(8):3752. doi: 10.1021/acs.jmedchem.8b00465. Epub 2018 Apr 5. J Med Chem. 2018. PMID: 29620363 No abstract available.
Neutral macrocyclic factor VIIa inhibitors.
Wurtz NR, Parkhurst BL, DeLucca I, Glunz PW, Jiang W, Zhang X, Cheney DL, Bozarth JM, Rendina AR, Wei A, Harper T, Luettgen JM, Wu Y, Wong PC, Seiffert DA, Wexler RR, Priestley ES. Wurtz NR, et al. Among authors: priestley es. Bioorg Med Chem Lett. 2017 Jun 15;27(12):2650-2654. doi: 10.1016/j.bmcl.2017.04.008. Epub 2017 Apr 19. Bioorg Med Chem Lett. 2017. PMID: 28460818
30 results